Company news: ViroPharma and DIME

Share this article:

Specialty drug company ViroPharma teamed with several medical societies on the launch of a program designed to unite specialists treating patients with the orphan condition hereditary angioedema (HAE). The main component of the program—called HAE: Learn About It, Talk About It—is the website LetsTalkHAE.com, which offers tools designed to readily diagnose and properly manage patients with the rare, potentially fatal swelling disorder. A joint effort initially targeting allergists and gastroenterologists, the program has grown to include NPs, PAs and emergency physicians. ViroPharma markets HAE therapy Cinryze.

Accredited med ed provider DIME launched a web browser designed to facilitate internet searching-and-learning, in which clinicians hunt online for answers to clinical questions in exchange for credit. The tool, called iPointOfCare, integrates across all browsers and devices and is optimized for the mobile environment, DIME said. About 116,000 physicians participated in this form of education in 2009, according to the ACCME.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.